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The Gram-positive anaerobic human pathogenic bacterium Atopobium vaginae
causes most diagnosed cases of bacterial vaginosis as well as opportunistic
infections in immunocompromised patients. In addition to its well-established role
in carbohydrate metabolism, D-glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
from Streptococcus pyogenes and S. pneumoniae have been reported to act as
extracellular virulence factors during streptococcal infections. Here, we report the crystal
structure of GAPDH from A. vaginae (AvGAPDH) at 2.19 Å resolution. The refined
model has a crystallographic Rfree of 22.6%. AvGAPDH is a homotetramer wherein each
subunit is bound to a nicotinamide adenine dinucleotide (NAD+) molecule. TheAvGAPDH
enzyme fulfills essential glycolytic as well as moonlight (non-glycolytic) functions, both
of which might be targets of chemotherapeutic intervention. We report that AvGAPDH
interacts in vitrowith the human C5a anaphylatoxin and inhibits C5a-specific granulocyte
chemotaxis, thereby suggesting the participation of AvGAPDH in complement-targeted
immunoevasion in a context of infection. The availability of high-quality structures of
AvGAPDH and other homologous virulence factors from Gram-positive pathogens is
critical for drug discovery programs. In this study, sequence and structural differences
between AvGAPDH and related bacterial and eukaryotic GAPDH enzymes are reported
in an effort to understand how to subvert the immunoevasive properties of GAPDH and
evaluate the potential of AvGAPDH as a druggable target.
Keywords: anaphylatoxin, chemoattraction, complement system, C5a, GAPDH (glyceraldehyde-3-phosphate
dehydrogenase), gram-positive pathogen, immunoevasion, x-ray crystallography
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INTRODUCTION
Atopobium vaginae is a Gram-positive anaerobic bacterium
of the Coriobacteriaceae family that is held responsible for
about 80% of diagnosed cases of bacterial vaginosis (BV) in
humans, a condition that can lead to obstetric complications and
gynecological disorders (Polatti, 2012; Datcu, 2014; Xiao et al.,
2016). Further, complications arising from A. vaginae infections
might range from predisposing to opportunistic infections by
HIV, type II Herpes simplex virus, and Chlamydia trachomatis
infections (Fredricks et al., 2005; Livengood, 2009) to late
abortion (Donati et al., 2010), premature rupture of the amniotic
membrane (McDonald et al., 2007), chorio-amnionitis (Fahey,
2008), post-partum endometritis (Sweet, 1995; Hillier et al.,
1996; Pellati et al., 2008), and failure of in vitro fertilization
and embryo transfer (Fredricks et al., 2005; Livengood, 2009).
Since an effective and long-lasting treatment for BV is not
available, with relapses occurring in about 30% of cases within a
month after treatment completion, new therapeutic approaches
are a necessity. Although the molecular basis for A. vaginae
infection, survival to currently used antibiotic treatments,
or the mechanisms behind the acquisition of resistance to
metronidazole showed by most strains (Chan et al., 2012;
Machado and Cerca, 2015) are not yet fully understood, they
are likely to involve many different genes encoding for biofilm
formation activities as well as for proteins with virulence and
immunoevasive properties.
Interestingly, phylogenetically diverse bacteria have been
shown to encode virulence factors that interfere with the
proper function of the human complement system, one of
the first barriers of defense against bacterial infections from
the innate immune system. One such virulence factor is the
glycolytic enzymeD-glyceraldehyde-3-phosphate dehydrogenase
(GAPDH, E.C. 1.2.1.12). To perform its glycolytic activity
GAPDH requires the nicotinamide adenine dinucleotide
(NAD+) cofactor that remains tightly bound in the active site.
The active site of GAPDH contains also two structurally distinct
phosphate-binding sites, the Pi and Ps sites, where inorganic
phosphate and the phosphate group from the glyceraldehyde-
3-phosphate (G3P) substrate bind, respectively, during reaction
(Skarzyn´ski et al., 1987; Yun et al., 2000). In fact, there are two
different Pi sites depending on the precise location within the
active site of the inorganic phosphate moiety, which are termed
the “classical” and “new” Pi sites (Yun et al., 2000; Mukherjee
et al., 2010).
The anaerobic lifestyle of A. vaginae implies that a functional
glycolytic pathway might be important to sustain infection,
therefore making A. vaginae (Av) GAPDH an interesting target
for the design of potent inhibitors. This proposal parallels
previous studies on GAPDH from trypanosomatid parasites such
as Leishmania mexicana (the causative agent of lepromatous
leprosy), Trypanosoma cruzi (Chagas’ disease) and T. brucei
(African sleeping sickness). These protozoan parasites cause
severely impairing diseases with a heavy death toll worldwide,
and the lack of wholly effective treatments for these diseases and
the problems associated with current drugs (toxicity effects and
resistance) have spurred the study of glycosomal trypanosomatid
GAPDH. The rationale for targeting trypanosomatid GAPDH
for drug discovery relies in the almost exclusive reliance of
trypanosomatids on the glycolysis to produce ATP. Indeed, the
structures of glycosomal GAPDH from trypanosomatid parasites
have been identified as potential drug targets because there are
substantial differences in the cavity forming the binding site of
the adenine ring of NAD+ cofactor between the human and
glycosomal GAPDH and in nearby hydrophobic cavities (Suresh
et al., 2001). Drugs targeting those hydrophobic cavities could
inhibit GAPDH through allosteric effects.
In addition to the known roles of GAPDH in the glycolytic
pathway, in the last years there has been an increasing awareness
that mammalian and bacterial GAPDH enzymes display many
other diverse functions. In mammals, GAPDH participates in
membrane fusion, microtubule bundling, nuclear RNA export,
DNA replication and repair and apoptosis, and it is in these non-
glycolytic roles that mammalian GAPDH has been associated
with various diseases including cancer (Zhang et al., 2015), viral
pathogenesis (Allonso et al., 2015), Huntington’s disease (Hwang
et al., 2015; Mikhaylova et al., 2016), Parkinson’s disease (Liu
et al., 2015) and Alzheimer’s disease (El Kadmiri et al., 2014).
Bacterial GAPDH enzymes have also shown a wide functional
repertoire (Henderson and Martin, 2014). In bacterial pathogens
encoding type III secretion systems, GAPDH has been shown
to be transported from the bacterial cell to the mammalian
host cell through the syringe system (Aguilera et al., 2012),
where GAPDH perturbs the redox balance of the attacked host
cell leading to its demise or to the creation of more favorable
environmental conditions for the invasive bacterial cells. It is
significant that GAPDH frommany different bacteria is exported
to the bacterial cell wall and the extracellular space, where
it seems to acquire functions that facilitate infection through
direct binding to innate immune proteins. This function has
been reported for S. pyogenes and S. pneumoniae through the
interaction of GAPDH with the human C5a anaphylatoxin,
which is implicated in inflammatory processes contributing to
both the innate and adaptive immune response, and with the
C1q complement factor that mediates interactions with IgG and
IgM (Terrasse et al., 2012), respectively. In the former case, a
solvent-exposed segment of S. pyogenesGAPDH spanning the N-
terminal 1−165 amino acid residues was identified as the likely
docking sequence for C5a (Terao et al., 2006). Other glycolytic
enzymes have also been demonstrated to undergo translocation
to the extracellular space where they acquire radically different
functions, oftentimes pro-infection roles (Agarwal et al., 2012).
It is intriguing to consider the possibility that AvGAPDH
might also be involved in fostering A. vaginae infection after
its secretion or translocation to the outside of the bacterial
cells by diminishing the ability of neutrophils to locate and
destroy the pathogen, lowering its antibody-mediated clearance,
or perturbing the normal immune response by other unexpected
pathways. Providing answers to these open questions will
hinge on a more thorough understanding of the structure
of AvGAPDH and its moonlighting functions in an infection
context.
Therapeutic action on the glycolytic or virulence-associated
functions of GAPDH represents an attractive route to help
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curb bacterial infections, while it depends on the availability of
specific drugs that can distinguish human GAPDH from the
targeted pathogen. The determination of the crystal structure of
AvGAPDH to 2.19-Å resolution provides a detailed description
of the overall structure of this enzyme as well as a high-quality
view into the active site. By comparing the AvGAPDH structure
with those of other pathogens and the available human GAPDH
structures, we have observed differences that provide insights
into the design of selective inhibitors. Furthermore, the analysis
of the peptide segment that corresponds to the C5a-bindingmotif
described for S. pyogenes GAPDH hinted at the possibility that
GAPDH enzymes from other Gram-positive pathogenic bacteria
could participate in the same strategy of infection regardless of
the exact colonization environment in the host organism (e.g.,
throat, lungs, vaginal flora). Binding assays with recombinant
C5a and cell migration inhibition assays by surface-immobilized
AvGAPDH of granulocytes challenged with zymosan-activated
serum (where native C5a is produced) have confirmed that
AvGAPDH could functionally act as a virulence factor, a
feature that might contribute to the infectivity and survival of
A. vaginae.
MATERIALS AND METHODS
Cloning
Genomic DNA from an A. vaginae type strain isolated from the
human vaginal flora of a healthy individual was purchased from
the DSMZ (DSM-15829). The gene encoding the 356-amino-
acid residue AvGAPDH (UniProt Accession No. F1T6A5) was
constructed by a two-step PCR protocol designed to incorporate
in the PCR amplicon an additional N-terminal hexahistidine
tag and a tobacco etch virus cleavage (TEV) site in frame with
the AvGAPDH gene. This PCR fragment was then inserted into
pET21b (Novagen) by restriction-ligation cloning. In addition
to the full-length construct, a PCR-amplified DNA sequence
encoding only the N-terminal fragment of AvGAPDH (residues
1−185) was subcloned in pGEX-6P-1 (GE Healthcare) fused in-
frame with the glutathione-S-transferase (GST) gene and a 3C
protease cleavage site. Expression plasmids for hexahistidine-
tagged S. pyogenes (Sp) GAPDH (UniProt Accession No.
P68777) and C. perfringens (Cp) GAPDH (UniProt Accession
No. Q0STD4) were constructed similarly to that of full-length
AvGAPDH.
Protein Expression and Purification
The expression plasmids were transformed into E. coli
Rossetta(DE3)pLysS cells (Novagen) and transformants
isolated in selective LB-agar plates. Transformants from a freshly
prepared plate or from a bacterial glycerol stock were used
to inoculate a 40-ml overnight starter culture from which a
larger culture (2 l) was initiated the next morning. The culture
was allowed to grow at 37◦C in LB or Power Broth (Athena)
media supplemented with 100µg/ml ampicillin and 35µg/ml
chloramphenicol to an absorbance of 0.6−0.8 at 600 nm and
the temperature was lowered to 20◦C for 1 h before induction.
The culture was then induced with 0.5 mM isopropyl β-D-
thiogalactopyranoside (IPTG) for 18 h. Cells were harvested
by centrifugation at 6,000 g for 20min at 4◦C and either used
immediately or stored at−80◦C until use.
For the hexahistidine-tagged full-length AvGAPDH, the
cell pellet from 2 l of culture was resuspended in 40 ml
of a buffer containing 50 mM Tris−HCl pH 8.0, 500 mM
NaCl, 20 mM imidazole and 1 mM phenylmethylsulfonyl
fluoride (PMSF), and cells were lysed by sonication. The
lysate was centrifuged at 20,000 × g for 30min at 4◦C and
clarified further by filtration through a 0.22µm membrane.
The purification procedure consisted of a capture step by
affinity chromatography in which the clarified lysate containing
N-terminal hexahistidine AvGAPDH was loaded on a 5-ml
HisTrap column (GE Healthcare) charged with nickel chloride.
AvGAPDH was eluted using a linear gradient of increasing
imidazole concentration (250 mM) over 20 column volumes.
Fractions containing AvGAPDH were pooled and dialyzed
against a buffer containing 50 mM Tris−HCl pH 8.0, 150
mM NaCl. Finally, AvGAPDH was subjected to gel filtration
chromatography over a HiLoad 16/60 Superdex 200 equilibrated
in a buffer consisting in 10 mM Tris−HCl pH 7.5, 150 mM
NaCl. We typically obtained 40 mg/l culture of pure AvGAPDH
with high purity, >95% pure on a Coomassie brilliant blue-
stained SDS-PAGE gel (Supplementary Figure 6A). Comparison
of the elution volume of AvGAPDH with a calibration curve
constructed using high and low molecular weight calibration
kits (GE Healthcare), following the recommended calibration
mixtures following the manufacturer’s instructions, corroborated
that the quaternary structure of AvGAPDH corresponds to a
homotetramer (Supplementary Figure 6B). Finally, AvGAPDH
was dialyzed against a salt-free buffer (10 mM Tris−HCl pH
7.5), concentrated to 30 mg/ml, dispensed in 30-µl aliquots,
snap-frozen in liquid nitrogen and stored away at −80◦C.
Expression (50 ml) and purification of hexahistidine-tagged full-
length SpGAPDH and CpGAPDH was carried out as indicated
for AvGAPDH.
For the GST-3C-fused AvGAPDH truncated protein (residues
1−185), the cell pellet from 100 ml of culture was resuspended
in 10 ml of a buffer containing 50 mM Tris−HCl pH 8.0,
150 mM NaCl, 10 mM EDTA, and 1 mM PMSF, and cells
were lysed by sonication. The lysate was centrifuged at 20,000
× g for 30 min at 4◦C and clarified further by filtration
through a 0.22µm membrane. The clarified lysate was then
loaded onto a column packed with 3 ml Glutathione Sepharose
4B beads (GE Healthcare), washed thoroughly with binding
buffer to baseline absorbance, and on-column tag cleavage
was then performed by overnight incubation with 3C protease
at 4◦C. Purified protein was recovered in the flow-through,
concentrated, and applied onto a Superdex 200 10/300GL
Increase gel filtration column equilibrated in a buffer consisting
in 10 mMHEPES−NaOH pH 7.4, 150 mMNaCl, 3.4 mM EDTA.
Peak fractions were analyzed by SDS-PAGE electrophoresis and
those fractions corresponding to the estimated molecular mass
for monomeric AvGAPDH 1−185 were pooled together for
further analyses.
The recombinant 74-amino-acid residue human C5a
anaphylatoxin (including the C-terminal Arg74) used in this
study can be obtained from Crelux GmbH.
Frontiers in Microbiology | www.frontiersin.org 3 April 2017 | Volume 8 | Article 541
Querol-García et al. A. vaginae GAPDH Interacts with C5a
Crystallization
Before attempting crystallization of AvGAPDH the required
number of aliquots was quickly thawed and centrifuged at
10,000 × g for 10 min at 4◦C to remove any potential aggregates
that might have resulted from a freezing-thawing cycle.
A commercial Pre-Crystallization Test (Hampton Research)
was used to adjust the protein concentration to a suitable
concentration for more extensive crystallization screenings,
which was finally set to 7.5 mg/ml. The full JCSG-plus sparse
matrix and the PACT premier systematic PEG/Ion/pH screenings
(Molecular Dimensions) were performed by the sitting-drop
vapor-diffusion method using drops containing 1µl AvGAPDH
at 7.5 mg/ml supplemented with 0.6 mM NAD+ and 1µl
crystallization condition at 20◦C.Moderately sized, plate or cube-
shaped crystals of AvGAPDH (100−200µm in their longest
dimension) appeared within 1 week under several conditions
from both commercial screenings. Two conditions were selected
for diffraction studies, condition 1 (0.1 M sodium citrate pH
5.5, 20% PEG 3000) and condition 2 (0.2 M sodium nitrate,
0.1 M Bis-Tris propane pH 8.5, 20% PEG 3350). Crystals were
then cryoprotected with 20% (v/v) sterile glycerol, mounted in
standard MicroMount (MiTeGen) and flash frozen in liquid
nitrogen.
Data Collection and Processing
Diffraction data were collected from flash-frozen crystals at 100
K using a photon-counting Pilatus 6M (DECTRIS Ltd, Baden,
Switzerland) at the BL13-XALOC beamline (ALBA, Barcelona,
Spain; Juanhuix et al., 2014). Crystals grown in either condition
1 or 2 diffracted to moderate-to-high resolution (2.19−2.5 Å)
and complete data sets were collected from both crystal forms,
indexed and processed with XDS (Kabsch, 2014) and scaled
and merged with Aimless (Evans and Murshudov, 2013) from
the CCP4 software suite (Winn et al., 2011). Crystals grown
under either condition were highly isomorphic, belonging to
space group P21, with unit-cell dimensions a = 71.4, b = 132.1,
c = 85.3 Å, and β = 104.9◦. Based on the data merging
statistics we selected condition 1 for structure determination.
The Matthews coefficient, VM, is 2.43 Å3/Da, indicates an
approximate solvent content of 49.3%. Merging of symmetry-
related reflections resulted in 77,410 unique reflections and a
multiplicity of 6.7 (6.4 in the last shell, 2.27−2.19 Å) with
an Rmeas value of 0.126 (0.904) and CC1/2 of 0.997 (0.881).
The completeness of the data to 2.19 Å was 98% (89%). Data
collection and processing statistics are summarized in Table 1.
Structure Determination
The structure was determined by the molecular replacement
method using the program PHASER (McCoy et al., 2007) from
the PHENIX program suite (Adams et al., 2011). Either the full
homotetramer (the biological unit) or a dimer of Staphylococcus
aureus GAPDH devoid of NAD+ (SaGAPDH; PDB ID 3LVF;
Mukherjee et al., 2010) were used as searchmodels after mutation
of the PDB file according to a sequence alignment (63% identity)
with CHAINSAW (Stein, 2008). Using the SaGAPDH tetramer
a single solution was found in the rotation and translation
searches with RFZ and TFZ of 30.0 and 15.4, respectively.
Rigid-body refinement as implemented in PHASER elicited
TABLE 1 | Crystallographic data collection and refinement statistics.
AvGAPDH Holoenzyme (PDB 5LD5)
DATA COLLECTION
Diffraction source ALBA BL13-XALOC
Wavelength (Å) 0.9795
Temperature (K) 100
Space group P 21
Cell dimensions
a, b, c (Å) 71.39, 132.11, 85.32
α, β, γ (◦) 90, 104.88, 90
Resolution range (Å) 47.71−2.19
(2.27−2.19)
Total reflections 518,896 (44,351)
Unique reflections 77,410 (6903)
Completeness (%) 99 (90)
Multiplicity 6.7 (6.4)
Mean I/σ(I) 9.46 (2.01)
Rmerge
a 0.116 (0.822)
Rmeas
b 0.126 (0.894)
Wilson B-factor (Å2) 37.96
CC1/2
c 0.997 (0.883)
CC*d 0.999 (0.968)
REFINEMENT AND VALIDATION
Reflections used in refinement 77,208 (7000)
Reflections used for R-free 3864 (351)
Rwork
e 0.177 (0.287)
Rfree
f 0.226 (0.324)
No. of non-H atoms
All 10,929
Protein 10,356
Ligands 248
Water 325
No. of protein residues 1362
R.m.s. deviations
Bond lengths (Å) 0.008
Bond angles (◦) 1.13
B-factors (Å2)
All 46.98
Protein 46.99
Ligands 47.11
Water 46.64
Number of TLS groups 14
Ramachandran plot
Favored (%) 97.1
Allowed (%) 2.9
Outliers (%) 0.0
Rotamer outliers (%) 0.62
Clashscore 6.15
Values for the highest resolution shell are given in parentheses.
aRmerge = 6h 6i |Ii (h)–<I(h)>|/6h 6i Ii (h), where h = (hkl), Ii (h) is the ith measurement and
<I(h)> is the weighted mean of all measurements of I(h).
bRmeas = 6h (n/n−1)
1/2 6ni |Ii (h)−<I(h)>|/6h 6i Ii (h), where n is the number of
independent observations of I(h).
cCC1/2 is the Pearson correlation coefficient calculated between two random half data
sets.
dCC* is the CC of the full data set against the true intensities, estimated from CC* = [2
CC1/2/(1 + CC1/2)]
1/2.
eRwork = 6h |FO−FC |/6h FO, where FO and FC are the observed and calculated structure
factor amplitudes of reflection h.
fRfree is as Rwork , but calculated with 5% of randomly chosen reflections omitted from
refinement.
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only minor improvements in correlation coefficient (CC) and
R factors. In contrast, using a dimer as the search model
led to the identification and subsequent use by PHASER of a
significant peak in the Patterson map indicating the presence
of pseudo translational symmetry. PHASER then switched on
the tNCS-enabled MR search that successfully identified two
independent solutions that together assembled the biological
homotetramer, with RFZ and TFZ scores of 19.2 and 13.2
for the first dimer plus the second, translationally symmetric,
dimer. The solutions were improved by rigid-body refinement
as implemented in PHASER, with R/Rfree factors of 0.39/0.40
for the tetrameric model and 0.40/0.40 for the solution obtained
with two dimeric models. At this stage both solutions were
indistinguishable (root-mean-square displacement, r.m.s.d., of
0.001 Å over 1,014 superimposed Cα atoms), hence we selected
the solution obtained with a full biological unit for further
refinement.
Model Building and Crystallographic
Refinement
An omit map calculated from the model phases before
(rigid) refinement or model building showed electron density
corresponding to four NAD+ molecules, one per protomer.
The complete homotetramer was then used for rigid-body
and maximum likelihood refinement in the resolution range
47.71−2.19 Å within phenix.refine (Afonine et al., 2012) setting
aside 5% of the reflections (selected randomly) to create a data
set of test reflections for cross-validation of the refinement
procedure. Refinement cycles were interspersed with cycles
of manual building (first, placing NAD+ and then solvent
molecules) and validation with Coot (Emsley et al., 2010).
Torsion-angle non-crystallographic symmetry restraints were
applied during the initial refinement but were removed during
the final refinement stages. Upon convergence, the refined
AvGAPDH model had Rwork/Rfree = 0.177/0.226 with good
stereochemistry. The final model consists of 340 residues of
each subunit, four NAD+ molecules, 325 water molecules
and 12 glycerol molecules (from the cryoprotectant solution).
Crystallographic refinement statistics are summarized in Table 1.
Enzyme Activity
The AvGAPDH enzyme activity was followed
spectrophotometrically by the change in absorbance at 340
nm due to NADH formation, according to a previously
described method (Ferdinand, 1964). Assays were performed
in an Eppendorf BioSpectrometer spectrophotometer at
25◦C. A standard assay was carried out in a final volume
of 0.15 ml in the presence of 40 mM Tris-HCl pH 8.5 and
2mM ethylenediaminetetraacetic acid (EDTA), 0.1µM of
purified enzyme, and indicated concentrations of substrates:
nicotinamide adenine dinucleotide (NAD+), glyceraldehyde-
3-phosphate (G3P) and inorganic phosphate (Pi). NAD+
concentration was varied between 0.03−2 mM, G3P
concentration between 0.6−15 mM, and Pi concentration
between 0.65−24 mM. Michaelis–Menten parameters, KM and
Vmax were obtained by nonlinear regression fitting of the kinetic
data using SigmaPlot v13.0 (Systat Software Inc.).
Sequence Conservation Analysis
GAPDH sequences of known structure and with a significant
degree of sequence similarity to AvGAPDH were found with
BLAST (Camacho et al., 2009) using sequences stored in the
PDB, aligned with MUSCLE and used to reconstruct a maximum
likelihood phylogenetic tree with PhyML (Guindon et al., 2010).
Ligand Blotting
A ligand blotting assay was set up to detect the interaction
between AvGAPDH and C5a essentially as described before
(Terao et al., 2006). Briefly, C5a was biotinylated using the ECL
Protein Biotinylation System (Amersham Biosciences) following
the manufacturer’s instructions. Then, different concentrations
of purified AvGAPDH were resolved on a 15% SDS-PAGE gel
and transferred to nitrocellulose membranes. The membranes
were blocked overnight at 4◦C with 10% membrane blocking
agent and treated with 50µg/ml biotinylated C5a for 1 h.
After extensively washing the membranes and incubating with
horseradish peroxidase (HRP)-labeled streptavidin at room
temperature for 1 h, C5a-containing bands were revealed with
luminol and hydrogen peroxide and subsequently visualized by
chemiluminescence on a Luminescent Image Analyzer LAS-3000
at room temperature.
Cross-Linking
Specific cross-linking assays with AvGAPDH were performed
with bis(maleimido)ethane (BMOE; Pierce 22322), a 7-atom,
8.0-Å short spacer arm cross-linking reagent that generates
non-cleavable cross-links between sulfhydryl groups that are in
close proximity. Cross-linking reactions were performed in assay
buffer (10 mM HEPES−NaOH pH 7.4, 150 mM NaCl, 3.4 mM
EDTA) containing 0.3 mM BMOE, incubated overnight at 4◦C,
and visualized by SDS-PAGE electrophoresis and Coomassie-
brilliant blue (CBB) staining.
Enzyme-Linked Immunosorbent Assays
The C5a interaction with AvGAPDH was studied also with an
enzyme-linked immunosorbent assay (ELISA). The wells of a
polysterene microtiter plate (F96 Maxisorp, Nunc) were coated
with 100µl of 10µg/ml of purified AvGAPDH in 50 mM
Tris−HCl pH 8.5 at 4◦C overnight. Wells were emptied and
washed with TBS-T (Tris-buffered saline pH 7.4 with 0.05%
w/v Tween-20) and the free sites on the plastic surface were
blocked with 1% BSA (bovine serum albumin) in TBS-T for 2 h at
37◦C. Uncoated wells and wells coated with AvGAPDHwere also
blocked. After washing extensively with TBS-T, various dilutions
of C5a in TBS (1–100µg/ml) were added to the AvGAPDH-
coated wells. The plate was incubated for 3 h at 37◦C and then
washed 4 times with TBS-T. A mouse anti-human C5a antibody
was added at a 1:2,500 dilution in TBS-T (100µl/well) and the
plate was incubated for 1 h at 37◦C and washed as before.
Next, a goat anti-mouse IgG-HRP conjugate (1:1000 dilution)
was added and the plate was incubated at 37◦C for 1 h. The
unbound conjugate was discarded and the plate was washed 5
times with TBS-T. OPD (o-phenylenediamine dihydrochloride)
substrate tables were dissolved in double distilled water and
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added immediately (100µl/well) to the plate. The absorbance was
measured at 495 nm in a microplate reader.
Immobilization of AvGAPDH
Purified full-length of AvGAPDH, SpGAPDH, and CpGAPDH,
and the 185-amino-acid N-terminal fragment of AvGAPDH
were immobilized by multipoint covalent binding on to
highly functionalized aminoethyl agarose (AM-4) beads (ABT,
40−60µmol aminoethyl/ml gel, 4% agarose), thereby allowing
protein immobilization through coupling with carboxylate
groups from exposed aspartate and glutamate residues and the
C terminus. The amount of covalently crosslinked GAPDH
was calculated from equation 1 below, where C0 is the protein
concentration at starting immobilization time and CF is the
protein concentration at final immobilization time:
Immobilization Yield (IY%) = 100× (C0 − CF)/C0 (1)
According to manufacturer instructions, 50µl of AM-4 resin was
rinsed with water and equilibrated with a buffer consisting of 10
mM Tris-HCl pH 7.6. The equilibrated resin was then activated
with 60 mM N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide
(EDC) and next various amounts of protein were incubated
with the treated resin at room temperature on an orbital shaker
with gentle stirring. At different times aliquots were removed
to monitor the amount of unreacted protein until it reached a
plateau (which occurred at about 3 h), indicating the saturation
of the accessible functional carboxylate groups on the resin. Next,
the suspension was centrifuged (13,500 rpm for 2min) and the
pelleted resin was carefully washed with water, 1 M NaCl, and
water again.
Migration Assays
After obtaining written informed consent from healthy donors,
human granulocytes were isolated from EDTA venous blood
samples by centrifugation on a Histopaque-1070/1119 gradient
(Sigma-Aldrich). These studies were performed according
to the principles expressed in the Declaration of Helsinki
and approved by the relevant Institutional Research Ethics
Committee. Residual erythrocytes were depleted by incubation
with 0.5 ml Ammonium-Chloride-Potassium Lysing Buffer (150
mM NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA, pH 7.2) for
2.5 min at 25◦C. Cells were washed twice with PBS (400 × g
for 6 min at 25◦C) and used at 2 × 105 cell/ml in RPMI-1640
(Sigma-Aldrich). Chemotactic migration was evaluated in 24-
well transwell plates with 5µm pore size polycarbonate filters
(Corning). 0.2 × 106 cells were loaded in the upper chambers,
while lower chambers contained 1 nM C5a (diluted from 48
nM C5a from zymosan-activated human serum, measured by
ELISA) pre-incubated for 1 h at RT with 15µl of either the
indicated GAPDH-linked or untreated resin beads in RPMI-
1640. Plates were then incubated for 30 min at 37◦C with
5% CO2. Using forward and side scatter gating, the number
of granulocytes recovered from lower chambers was quantified
by flow cytometry for 1.5 min (constant flux acquisition,
FACSCalibur, BD Biosciences). Normal migration to 1 nM C5a
preincubated with untreated resin beads was 5,841 ± 2,141 cells,
background migration to EDTA-containing human serum with
undetectable C5a by ELISA was 510 ± 245 cells. Migration after
preincubation with GAPDH resin beads was expressed relative
to normal migration after preincubation with the same amount
of untreated resin beads. Statistical analysis and graphical
representation were done using the R software.
RESULTS
Overall Structure
The crystal structure of AvGAPDH has been solved at 2.19
Å resolution and a complete macromolecular model has been
built and refined with correct stereochemical parameters. Upon
convergence, the crystallographic R factors were Rwork/Rfree =
0.177/0.226.Table 1 contains the X-ray diffraction data collection
and refinement statistics. The overall structure and domain
architecture of AvGAPDH closely resemble those described in
previous GAPDH structures. The quaternary structure shows
four subunits designatedO, P,Q, andRwith three non-equivalent
intersubunit interfaces related by three mutually perpendicular
dyad axes (P, Q, and R; nomenclature consistent with PDB code
1CER; Tanner et al., 1996) and one NAD+ molecule bound
per active site, which is clearly defined in electron density
(Buehner et al., 1974; Roitel et al., 2003). The four monomers in
the GAPDH homotetramer are not necessarily equivalent since
previous studies have indicated the presence of negative allosteric
effects across subunits (Nagradova, 2001). In the final model
of AvGAPDH, the tetramer shows minor deviations of <0.2◦
from the ideal 222 (D2) molecular symmetry (Figure 1A). The
AvGAPDH homotetramer contains three asymmetric interfaces
between each protomer and the adjacent subunits. The O-P
interface contains the largest buried solvent area (1,830 Å2) and
includes about 30 hydrogen bonds and 12 salt bridges. The
second largest interface is the O-R interface, with 1,325 Å2, and
is formed by 10 hydrogen bonds and 2 salt bridges. Finally, the
smallest of the three interfaces, between theO-Q subunits, covers
about 500 Å2 and includes 11 hydrogen bonds and 4 salt bridges.
AvGAPDH is characterized by an N-terminal NAD+-binding
domain (residues 1−167) and a C-terminal catalytic domain
(residues 168−356; Harris and Waters, 1976). The N-terminal
NAD+-binding domain features the classical α/β dinucleotide-
binding fold or Rossmann fold (Figures 1B,C). It folds into
eight β-sheets (βA-βH) connected by helices and short loops.
The helices of the N-terminal domain are α1-α2, which are
located before and after βB, and three 310 helices: 310A, which
immediately precedes βC, βD, and βE, and 310B followed by α3-
α4. The third 310 helix (310C) connects an extended section with
a central isolated β-bridge centered at Ile147 with the last β-
strand (βH) of the NAD+-binding domain. Overall, the structural
tandem β-α-β-α-β motif is conserved (Lesk, 1995; Antonyuk
et al., 2003). The C-terminal domain consists of a seven-stranded
mixed parallel β-sheet (βI-βP), three α-helices (α4-α6) there are
six 310 helices that are found immediately before or following
β-strands (Figures 1B,C). Helices 310D-F are located between βJ-
βK strands, while 310G, 310H and 310I are placed after βJ, βK,and
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FIGURE 1 | Overall architecture of the homotetrameric AvGAPDH. (A) The AvGAPDH homotetramer subunits O, P, Q, and R are shown in yellow, cyan, violet,
and orange, respectively. In the active site of each protomer there is one NAD+ bound (black). Symmetry axes are shown as dashed arrows, with the Q axis shown
perpendicular to the plane of the paper. (B) Ribbon representation of the AvGAPDH monomer with secondary structural elements labeled. Helices are colored in cyan,
310 helices in orange, strands in violet, and interconnecting segments in pink. The cofactor molecule is not shown for clarity. (C) Shown in the same orientation as in
(B), the two domains of AvGAPDH are mapped in two distinct colors on a molecular surface representation. The N-terminal cofactor-binding domain is mapped in
orange and the C-terminal catalytic domain in violet. NAD+ atoms are depicted as spheres in CPK colors. The figure was produced with PyMOL (Schrodinger LLC).
βP-α7, respectively, with α6 between the βL-βM strands. The N-
terminal NAD+-binding domain and the C-terminal catalytic
domain are bridged at the joint between strand βH and the long
helix α4. The catalytically active nucleophile Cys168 and the
activating His195 lie at the beginning of helix α5 and the end
of the following strand, βI, respectively. The C-terminal α6 helix
is inserted into an extensive groove of the N-terminal domain
where it forms a significant part of the interdomain interface and
contributes to the binding pocket for the nicotinamide ring of the
NAD+ cofactor. No traces of a phosphate ion were found bound
into the active site.
The distance between the active-site Cys168 sulfhydryl to
the Nε2 atom of the active-site His195 is 3.39–3.45 Å in
chains O and R and 3.64 Å in chains Q and R, which is
consistent with the defined closed conformation for the reported
structure of homotetrameric AvGAPDH. Differences in cofactor
binding between the subunits of GAPDH from various sources
have been previously postulated as the basis for the negative
cooperativity observed in NAD+ binding, where the first two
NAD+ molecules bind with a higher affinity than the third and
fourth NAD+ molecules (100−300-fold less tightly; Nagradova,
2001), although this asymmetry has not been demonstrated for
every GAPDH. In particular, no negative co-operativity was
observed in trypanosomatid GAPDH enzymes (Lambeir et al.,
1991).
The crystal structure of AvGAPDH presents the closed
conformation of the enzyme. In support of a closed
conformation, the conformation of the NAD+-bound
AvGAPDH is significantly more similar to the structure of
NAD+-bound Bacillus stearothermophilus (Bs) GAPDH (PDB
ID 1GD1) than to the NAD+-free form (PDB ID 2GD1;
Skarzyn´ski and Wonacott, 1988) as shown by the corresponding
r.m.s.d. values (1.35 Å vs. 1.54 Å, respectively). AvGADPH in
solution is likely to be more flexible or have more disordered
surface loops than the closed enzyme conformation.
In many GAPDH structures a conserved Val residue adopts
a highly strained backbone conformation (Kim et al., 1995),
within the most disallowed region of the Ramachandran plot, in
order to help maintain a hydrogen bond interaction between a
critical Asn and the nicotinamide ring of NAD+ (Souza et al.,
1998). In contrast, the equivalent residue in AvGAPDH, Gly257,
establishes a hydrogen bond with Asn336 through its main-chain
amide that has a similar length (2.9−3.1 Å) and orientation
as the more commonly found Val-Asn hydrogen bond. This
isofunctional Val to Gly substitution has also been observed in
S. aureus and Thermotoga maritima GAPDH (Korndörfer et al.,
1995; Mukherjee et al., 2010).
The Active Site and Cofactor-Binding Site are
Located in a Large Conserved Groove
An omit map calculated with molecular replacement phases
(prior to refinement) around the catalytic Cys168 of all subunits
(Supplementary Figure 1) confirms the absence of covalent
oxidation modifications that would inactivate AvGAPDH, as
those present in previously reported GAPDH structures, which
have been explained as oxidation of the cysteine residue to
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sulfonic acid or S-oxyl cysteine (Cowan-Jacob et al., 2003).
His195, which assists Cys168 by increasing its nucleophilicity, is
itself polarized by interactions with the catalytically important
residue Arg251 (Nagradova, 2001). The conformation adopted
by Arg251 side chain allows it to form hydrogen bonds with
Asp200 and the nearby Gln201 side chains, on the opposite side
to His195. Similar polarizing interactions between Arg residues
with Asp carboxylates have been described to facilitate catalysis
by lowering the pKa of Arg251 for the guanidinium side chain
from 12.5 to 9.0 (Kuzminskaya et al., 1991; Cowan-Jacob et al.,
2003).
NAD+ molecules are tightly bound in an elongated cleft in
all four protomers of the homotetrameric AvGAPDH structure
(Figures 1A, 2A). The presence and occupancy of NAD+ was
assessed with unbiased omit maps (Figure 2B). The nicotinamide
group is deeply embedded in the protein, as suggested by
the similar or even lower B-factors of the NAD+ molecules
(36.8−49.2 Å2) in comparison with the average B-factors for
the protein chain (43.0−52.1 Å2). The atomic B-factors for the
adenine moiety are between 2.0 Å2 lower and 8.5 Å2 higher
than the atomic B-factors for the nicotinamide part of the same
NAD+ molecule, thereby indicating a well-defined conformation
for the adenine group in all chains (Figures 2, 3). Furthermore,
the electron-density real-space correlation coefficient (RSCC) for
the NAD+ molecules is 0.94−0.97 (0.90 overall), indicating that
the NAD+-binding pocket is fully and equally occupied in all
four protomers (Figures 2B, 3A). The relatively low B-factors
and near-unity RSCC for the NAD+ molecules argue for a very
tight binding of the cofactor into the NAD+-binding pocket.
Most residues involved in cofactor binding are completely
conserved between AvGAPDH and human GAPDH. However,
there are several substitutions in the cofactor-binding site,
especially in residues located around the entry gateway.
Specifically, Pro36, Phe37, and Arg80 in human liver GAPDH
are substituted in AvGAPDH by Asp49, Leu50, and Ala95,
respectively (Figures 2A, 3A). Structurally, the smaller aliphatic
side chain of Leu50 fulfills essentially the same role as Phe37
in the human enzyme, although they build slightly different
hydrophobic environments that might be exploited by selective
drug targeting. The loss of the positively charged Arg80 present
in human GAPDH is likely inconsequential for NAD+ binding,
since Arg80, exactly as Ala95 in AvGAPDH, interacts with the
cofactor via a main-chain carbonyl hydrogen bond. Interestingly,
in Plasmodium falciparum (Satchell et al., 2005) the equivalent
FIGURE 2 | NAD+ and phosphate binding sites in AvGAPDH. (A) Binding pockets for the NAD+ cofactor (shown in sticks with carbon atoms in gray and all
other atoms in CPK colors) and for the inorganic and substrate phosphate sites (“new Pi” and Ps sites, labeled). The placement of the Pi site in AvGAPDH as a “new
Pi” site is consistent with the S. aureus GAPDH structure (PDB ID 3K73). Enzyme residues in direct contact with NAD
+ are represented in sticks (carbon atoms in light
green) and polar interactions (hydrogen bonds) are depicted as dotted lines. Residues predicted to participate in the stabilization of the inorganic and substrate
phosphate groups (including the catalytic Cys168) are also shown as sticks (with carbon atoms in two different shades of dark green). The AvGAPDH structural
scaffold is shown in ribbons in depth-cued light colors. (B) Omit map showing unbiased electron density map of NAD+ cofactor in AvGAPDH. Unbiased omit map
calculated with molecular replacement phases (prior to building the cofactor and solvent structures and prior to refinement) contoured at 1.5 σ revealing the presence
of the NAD+ cofactor at full occupancy. For comparison, electron density map for the final model of the NAD+ cofactor displayed at the same contour level (right).
The figure was produced with PyMOL (Schrodinger LLC).
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FIGURE 3 | Active site features of AvGAPDH. AvGAPDH is shown in cartoon representation (gray; NAD+ binding site is in gold; and AvGAPDH-specific residues
in the S loop in violet). (A) Network of interactions that stabilizes NAD+ binding. The main and side chains of NAD+-binding residues are shown in stick
representation. Key water molecules are shown as red spheres. They are overlaid with the σA-weighted (2mFO−DFC) electron density map contoured at 1 σ level.
Asterisks denote residues belonging to the neighboring subunit. (B) Continuation of the S loop (residues Ala196-Ile223, in gold) beyond the NAD+ binding site,
depicting its elongated, irregular shape. Residues are overlaid with the σA-weighted (2mFO−DFC) electron density map contoured at 1 σ level. The figure was
produced with PyMOL (Schrodinger LLC).
position is occupied by a Lys, thereby suggesting that a positively
charged side chain might play a secondary functional role in
NAD+ and/or substrate binding/release. A network of water
molecules further contributes to stabilizing the bound NAD+
conformation in the active site by holding in place the adenosyl
and nicotinamide rings and the nucleotide linking phosphate
groups (Supplementary Figure 2).
Phosphate Sites
Since the Pi and Ps sites (Supplementary Figure 3) supply
essential functions, the GAPDH residues involved in shaping
them are highly conserved across very divergent species
(Supplementary Figure 4). While the Ps site has been found at
an identical location across all known prokaryotic and eukaryotic
GAPDH structures, two distinct Pi sites have been described. The
so-called “classical Pi” site is modeled after the BsGAPDH co-
crystallized with sulfate anions (PDB ID 1GD1, sequence identity:
50.3%; Skarzyn´ski et al., 1987), whereas a “new Pi” site was
first characterized in T. maritima (Tm) GAPDH (Korndörfer
et al., 1995) and subsequently corroborated in Escherichia coli
(Ec) GAPDH and S. aureus (Sa) GAPDH structures (Yun et al.,
2000; Mukherjee et al., 2010). Their different locations within
the GAPDH active site is explained by the differential placement
of the β-strand-loop-α-helix stretch spanning residues 226−231,
which is more deeply buried in those structures with a “new
Pi” site. The strand-loop-helix motif residues in AvGAPDH were
all clearly defined in electron density maps. In the AvGAPDH
structure there is no residual electron density at the Pi, “new
Pi,” or Ps sites, indicating that they were completely unoccupied
in the crystal (Supplementary Figure 4B). By analogy with most
GAPDHs of known structure that have been crystallized with
inorganic phosphate or sulfate, we could assign the four residues
that contribute to the canonical Ps site: Thr195 (Oγ atom),
Asp200 (side-chain carboxylate), Arg251 (guanidinium group),
and NAD+ (2′ hydroxyl of the nicotinamide-ribose part, O2D;
Supplementary Figure 3A). A conformational switch involving
Arg251 has been proposed to play an important role in the
regulation of the substrate G3P binding and the release of the
product, 1,3-bisphosphoglycerate (1,3-BPG; Souza et al., 1998).
Inspection of the conformation adopted by the 226−231 loop
of AvGAPDH indicates that its Pi site is most likely a “new
Pi” site analogous to that of SaGAPDH, which would recruit
the side chains of Ser167, His195, Thr228, and Arg251, and
the main-chain carbonyl and side-chain hydroxyl of Thr169
(Supplementary Figures 3B, 4). The neighboring residue Arg215
can interact with the side chain of Asp200 to stabilize its
position and, conceivably, could also support a product-release
mechanism whereby Arg215 would interact with the phosphate
moieties of 1,3-BPG thereby displacing the similar interaction
with Arg251, which is part of both the “new Pi” and the Ps sites.
This displacement would require the side chains of Asp200 and
Arg215 to flip in and out according to the substrate binding state
of AvGAPDH (Supplementary Figure 4).
S Loop
An important structural feature of the active site of GAPDH
is the S loop, a long winding region folded into an irregular
shape along the R dyad groove spanning residues Ala196-
Ile223 (Figures 3A,B) around the P dyad (Biesecker et al., 1977;
Skarzyn´ski et al., 1987). Residues in the S loop contribute to
a complex interaction network that includes hydrophobic and
ionic contacts around the R axis and ionic contacts around the
P dyad (Skarzyn´ski et al., 1987; Biesecker et al., 1977). Pro207
forms one side of the binding pocket for the adenine-ribose
moiety of the NAD+ bound to a neighboring subunit related
by the R axis (Figure 3A). Despite the overall conservation of
the peculiar S loop sequence in AvGAPDH, there are several
substitutions plus a Gly211 insertion at Ile203-Arg217 in the
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middle of the S loop (Figure 3B). These modifications cause
the protrusion of a turn containing both positively charged
side chains (Arg209 and Lys210) toward the crevice where the
nicotinamide-ribose moiety of NAD+ is located, whereas in most
GAPDHs the equivalent turn contains only one conserved Lys
(Lys197 in human liver GAPDH; Figure 4A). Electron density
for the side chains of Arg209 and Lys210 is weak (Figure 3B),
which is attributed to the high thermal parameters of side-chain
atoms (backbone atoms have low B-factors). In particular, there
is no visible electron density for the Cγ-Nε atoms of Arg209
and Cε-Nζ atoms of Lys210 at 1 σ contour level, although the
clearly visible electron density for the first side-chain atoms (Cα-
Cβ-Cγ) unambiguously (Figure 3B). The Cα atoms of Arg209
and Lys210 are roughly equidistant (14.1−15.6 Å and 12−13.1
Å) from the N7 atom of the adenine moieties in the cofactors
bound to the O and R subunits. The closest distance between
either side chain in a fully extended conformation and NAD+
is 7.5 Å. In addition, residues Leu204 and Asp205 are conserved
and interact with the cofactor through water mediated and main
chain interactions (Figure 4A and Supplementary Figure 3). It
is remarkable the conservation between the human and the
AvGAPDH enzymes at and around the entry gateway to the
adenine ring of NAD+, in particular Val101 (Phe116) and Phe37-
Leu50 (Figures 3A, 4C). A Phe in place of Val101 should present
steric clashes with Pro82 and Ala97 in AvGAPDH, therefore it
appears that this change in sequence has a structural role.
Structural Similarity with SaGAPDH
The closest structural homolog of AvGAPDH is SaGAPDH (PDB
ID 3K73; Mukherjee et al., 2010) with an r.m.s.d. value of 1.35 Å
when the complete quaternary structures are superimposed (0.96
Å on average when each pair of monomers are superimposed),
and 63% sequence identity. The structures of AvGAPDH and
SaGAPDH are therefore considerably conserved, with most
differences concentrating in loops and connection regions. For
instance, the α1-βB junction is different in the two enzymes,
FIGURE 4 | Structural comparison of AvGAPDH and human liver GAPDH. Ribbon representations of the AvGAPDH and human liver GAPDH (PDB ID 1ZNQ)
holoenzymes in gray. The molecular surfaces of two subunits are shown in wheat color. The NAD+ cofactor bound to the two subunits represented as ribbons are
shown as sphere models in CPK color. Regions where structural differences are more prominent are shown in teal, boxed, and magnified as panels (A–C). (A) S loop.
(B) Structurally distinct loop regions on the outer surface of AvGAPDH. (C) Adenine ring subpocket of the active site. Several pharmacologically relevant compounds
have been discovered that target the adenine ring subpocket of GAPDH from trypanosomatids. The superposition, molecular surface, and (A–C) were produced with
PyMOL (Schrodinger LLC). (D) Sequence alignment including the protein sequences of AvGAPDH and human liver GAPDH.
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leading to a retraction of the peptide chain that causes a
broadening of a solvent-exposed groove over the active site
in AvGAPDH. In addition, several 310 helices in AvGAPDH
are absent in SaGAPDH, which are responsible for some
local structural deviations; for example, 310A (residues 69−71),
which protrudes toward the interface between the two adjacent
subunits, has a maximum displacement to the corresponding
segment in SaGAPDH of 4.7 Å. On this face of AvGAPDH,
the structural differences at helix 310A are further amplified by
additional local changes at the loop connecting the following
strands (βB-βC). Likewise, the loop spanning Gly141-Asp143
shifts toward the entryway to the active site, contributing to the
closing of the NAD+-binding pocket, with a maximum distance
deviation of 5.5 Å at the center of the loop. Finally, concerted
changes affecting the βL-α6 loop and the strands βO and βP
(spanning residues 266−287 and 319−326, respectively) in a fully
solvent exposed area lead to severe main-chain displacements as
large as 4.29 Å.
Kinetic Analysis
To compare the catalytic efficiency ofAvGAPDHwith SaGAPDH
and other homologous enzymes, we measured its kinetic
parameters for the direct reaction by systematically varying
NAD+, G3P, and Pi concentrations. The results are shown in
Table 2. For G3P, for which there are more complete kinetic
data for SaGAPDH, the kcat rate constants of the two enzymes
were pretty similar; however, the 10-fold higher KM for G3P
determined forAvGAPDH in comparisonwith that of SaGAPDH
resulted in a correspondingly 10-fold lower kcat/KM ratio. It
is interesting than the KM for NAD+ is smaller than for the
co-substrate, G3P, by a factor of 30.
AvGAPDH Interacts with the Human C5a
Anaphylatoxin
In addition to the essential glycolytic role of AvGAPDH,
we investigated whether AvGAPDH could function as a
virulence factor by sequestering the human C5a anaphylatoxin,
a complement factor 5 (C5)-derived proteolytic activation
fragment which diffuses out of the area wherein C5 is activated
to chemoattract neutrophils and macrophages (Marder et al.,
1985; Guo and Ward, 2005). This C5a-inhibitory function had
been previously observed for S. pyogenes (Sp) GAPDH (Terao
TABLE 2 | Kinetic parameters.
KM VM kcat kcat/KM
GAPDH Substrate (mM) (mM s−1 mg−1) (s−1) (mM−1 s−1)
A. vaginae G3P 2.6 ± 0.5 5.7 ± 0.3 57 ± 6 22 ± 5
NAD+ 0.08 ± 0.03 3.1 ± 0.2 31 ± 3 384 ± 150
Pi 3.4 ± 0.6 2.9 ± 0.2 29 ± 3 8 ± 2
S. aureusa G3P 0.32 n.d. 70 218.8
NAD+ 0.316 n.d. n.d. n.d.
Pi 2.57 n.d. n.d. n.d.
aThe kinetic parameters of SaGAPDH were taken from Mukherjee et al. (2010).
et al., 2006), and it requires the translocation of GAPDH
to the cell wall or the extracellular medium, a process that
has been described for GAPDH enzymes from a variety of
prokaryotic and eukaryotic organisms (Aguilera et al., 2012).
Although it is still unknown whether AvGAPDH is displayed
on A. vaginae cells, it is a conceivable scenario that could play
an important function in the long-term survival strategy of the
pathogen. Since the AvGAPDH and SpGAPDH sequences share
a 60% sequence identity, we investigated whether both proteins
could also share the immunoevasive function described for the
S. pyogenes enzyme.
In order to test the possible interaction between AvGAPDH
and C5a we conducted three sets of experiments. Firstly, we
evaluated whether biotinylated C5a could bind to membrane-
immobilized AvGAPDH in ligand blotting experiments, which
have been used before to demonstrate an interaction between
SpGAPDH and C5a (Terao et al., 2006). The results show that
biotinylated C5a accumulates rather specifically onto AvGAPDH
bands in a quantitative fashion (Figure 5A), thereby indicating
that a complex between membrane-immobilized AvGAPDH and
biotinylated C5a does indeed form. This is to be expected of an
interaction between the fluid-phase C5a and cell wall-associated
AvGAPDH. In comparison, it is noteworthy the absence of
a signal on the negative control (BSA lane) and the strong
signal from the positive control (C5a lane, which contains
biotinylated C5a).
Secondly, we tested the AvGAPDH-C5a interaction in
solution using natively folded AvGAPDH with the highly specific
cross-linking reagent BMOE, which tethers together Cys residues
that lie in close proximity (typically, within 8 Å). As shown in
Figure 5B, cross-linked AvGAPDH-C5a bands developed that
prove that a native interaction exists betweenAvGAPDH andC5a
that involves surfaces containing a Cys residue in AvGAPDH and
the only free Cys in C5a (Cys704). Treating C5a or AvGAPDH
alone with BMOE confirmed that no cross-linking species is
generated, thereby ensuring the specificity of the interactions
captured by BMOE. However, increasing C5a amounts led to
the progressive appearance of a C5a-AvGAPDH complex, which
runs with an apparent molecular mass ca. 10 kDa greater than
AvGAPDH (Figure 5B, arrow), corresponding to the mass of
C5a. As the electrophoretic band containing cross-linked C5a-
AvGAPDH species becomes more intense, the amount of free
AvGAPDH becomes lower in proportion, further arguing in
favor of a quantitative interaction. In parallel, the amount of
free biotinylated C5a unreacted with BMOE is significantly
lower than in the corresponding BMOE-treated control lane,
thus indicating a proportional reduction of both free species
as the amount of cross-linked complex increases. While the
involvement of Cys704 of C5a uniquely defines the interaction
surface for C5a, there remains an ambiguity in assigning
the surface area on AvGAPDH engaged for interaction with
C5a. While the N-terminal fragment 1−165 of SpGAPDH was
sufficient to elicit the interaction with C5a (Terao et al., 2006),
an analogous C-terminally truncated version of AvGAPDH
(residues 1−185) was only able to bind C5a in the same
degree than the full-length enzyme in ligand blotting and cross-
linking assays, but not in other functional assays (cf. below).
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FIGURE 5 | AvGAPDH interacts with human C5a. (A) Detection of C5a interaction by full-length AvGAPDH in ligand blotting experiments. Top, Coomassie brilliant
blue (CBB)-stained SDS-PAGE gel where BSA (negative control), biotinylated C5a (positive control, detectable without added biotinylated C5a), and increasing
amounts of pure AvGAPDH (1−32µg) were separated. Bottom, ligand blotting was conducted after the electrotransfer of the same SDS-PAGE gel shown on top onto
nitrocellulose membrane by incubating the membrane with biotinylated C5a and developing the blot with horse radish peroxidase (HRP)-conjugated anti-biotin
antibody and luminol. (B) Crosslinking of AvGAPDH and C5a with BMOE shown on a CBB-stained SDS-PAGE gel loaded with mock-treated control samples (C5a
and AvGAPDH, GAP) and BMOE-treated crosslinked samples (increasing concentrations of C5a for a fixed concentration of AvGAPDH). The two first lanes with
added BMOE represent internal controls for C5a (maximum load) and AvGAPDH (no C5a). In (A) and (B) arrowheads point to the bands where AvGAPDH and C5a
co-localize. (C) C5a bound to AvGAPDH immobilized on a polystyrene microtiter plate measured by an ELISA assay. The absorbance at 495 nm is plotted against
increasing C5a concentrations. Data represents mean ± SD (standard deviation; N = 3).
This indicates that the complete AvGAPDH-C5a interaction
surface may engage a more extensive region of AvGAPDH than
encompassed by the N-terminal deletion construct.
Finally, we also studied the interaction between AvGAPDH
and C5a using an enzyme-linked immunosorbent assay (ELISA).
In this assay, surface-immobilized AvGAPDH was capable of
binding C5a in a concentration-dependent manner (Figure 5C),
whereas uncoated wells or AvGAPDH-coated wells that had not
been treated with C5a elicited no significant background signal.
Inhibition of C5a-Specific Granulocyte
Chemotaxis by Recombinant GAPDH
Variants
To provide further evidence for a potentially immunoevasive
function for AvGAPH, we next investigated whether AvGAPDH
was able to inhibit granulocyte (mainly neutrophils) motility,
a C5a-specific cellular response that is relevant in the context
of bacterial infections. Based on the known interaction surface
of SpGAPDH and the binding experiments described for
AvGAPDH, we would expect that AvGAPDH could bind
C5a through surface areas located close to the N terminus
of AvGAPDH (Figure 6A). We tested surface-immobilized
AvGAPDH by challenging blood-purified human granulocytes
in presence of zymosan-activated serum, which contains
native human C5a, with increasing concentrations of soluble
AvGAPDH and two different amounts of AvGAPDH-bound
resin beads, and measuring the inhibition of neutrophil
chemotaxis in a cell migration assay (Figure 6B). The resin-
immobilized AvGAPDH contained 53µg/µl full-length
AvGAPDH (80−85% immobilization yield), therefore providing
a dense surface distribution of AvGAPDH on the resin beads.
As positive controls for both experimental designs, we used
immobilized SpGAPDH. Lastly, we also used GAPDH from
Clostridium perfringens (Cp) as a third related protein to assess
the capacity of GAPDH enzymes with varying sequences to
inhibit C5a-induced cell migration.
The cell migration assays convincingly showed that resin-
bound full-length AvGAPDH could reduce the amount of C5a-
mediated transmigration of granulocytes in our cell-based assay
(Figure 6B). The marked reduction in cell migration elicited by
preincubating beads coated withAvGAPDH (or SpGAPDH) with
the activated C5a serum strongly suggested that a direct, physical
interaction between AvGAPDH and C5a as the likely mechanism
for cell motility arrest. The inhibitory effect of AvGAPDH
on granulocyte migration was significant (p = 0.017) and
approximately equivalent to that achieved by the same amount
of SpGAPDH-immobilized beads (p= 0.001), thereby indicating
that the neutralization of C5a by A. vaginae might be as efficient
as during S. pyogenes infection. Interestingly, CpGAPDH failed
to significantly block granulocyte motility at the concentrations
tested (p = 0.056), thereby indicating a sequence-dependent
effect of GAPDH-mediated inhibition. The varying degrees
of cell migration inhibition, in turn, could reflect upon the
varying concentrations of C5a in their respective infection sites
in humans and their different mechanisms for infection and
immunoevasion. Although the amounts of AvGAPDH used in
these assays are larger than in comparable antagonist-based
assays (e.g., Huber-Lang et al., 2002), the increase in avidity
caused by the cell surface display ofAvGAPDH could compensate
for the apparent lower binding strength, a binding-potentiating
effect that would be even more pronounced during infection,
when A. vaginae cells typically grow in a highly concentrated
biofilm.
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FIGURE 6 | Inhibition of C5a-specific granulocyte chemotaxis by recombinant AvGAPDH variants. (A) Molecular surface of the AvGAPDH tetramer in two
views related by a 90◦ rotation through a vertical axis. Residues 1−185 of AvGAPDH of each protomer, which correspond to the C5a-binding region defined for
S. pyogenes GAPDH (Terao et al., 2006), are shown in gray, while the remaining C-terminal sequence is shown in chain-specific colors. The black box surrounding
one N terminus (NAD+ atoms are represented as spheres and colored in CPK) is shown as an enlarged view with AvGAPDH structural elements in ribbon
representation. (B) The boxplot graph shows the results of a transmigration experiment of human granulocytes towards a C5a-containing lower chamber expressed
as percent migration (mean ± SEM of 3−4 independent experiments). All results are normalized to the migration of human granulocytes elicited by 0.96 nM C5a
incubated with the corresponding amount of uncoated aminoethyl agarose (AM-4) resin beads, taken as 100%; background signal at 0 nM C5a is 4.8%, shown for
comparison. The remaining migration experiments were conducted by pre-incubating 0.96 nM C5a with aminoethyl agarose (AM-4) resin beads, either mock
(uncoated resin beads) or with covalently immobilized GAPDH molecules. Besides the C5a control, from left to right, the bar graph shows mock AM-4 beads, AM-4
beads with full-length GAPDH from S. pyogenes, C. perfringens, and A. vaginae. Migration inhibition percentages were normalized to the amount of GAPDH
effectively coating the beads. The p-values shown above the boxplots for GAPDH-coated beads were calculated with the R software.
The reported interaction between AvGAPDH and C5a
and the inhibitory effect that AvGAPDH has on C5a-
induced granulocyte migration may arguably play a role
in A. vaginae survival during infection by combating pro-
inflammatory defense mechanisms mounted by the human
immune system. Specifically, colonization and infection of the
vaginal tract by A. vaginae and other pathogenic bacteria
such as Gardnerella vaginalis are characterized by triggering
an intense inflammatory response with the liberation of
interleukins IL-6 and IL-8, which is not elicited by the
microbiota of healthy individuals, and that is essential for
the pathogenesis (Fichorova et al., 2011; Doerflinger et al.,
2014).
Sequence Conservation Analysis
GAPDH sequences of known structure and with a significant
degree of sequence similarity to AvGAPDH were found with
BLAST (Camacho et al., 2009) using sequences stored in the
PDB, aligned with MUSCLE and used to reconstruct a maximum
likelihood phylogenetic tree with PhyML (Guindon et al., 2010;
Figure 7).
Implications for AvGAPDH-Inhibitor Design
of Trypanosomatid GAPDH Inhibitors
In the absence of an efficient treatment for A. vaginae infection
and the possibility that AvGAPDH could participate in the
onset and maintenance of the pathogen through both metabolic
and immunoevasive strategies, we considered whether available
GAPDH inhibitors targeting trypanosomatid GAPDH enzymes,
which escape binding to human liver GAPDH, could be used to
block AvGAPDH. The overall structure of AvGAPDH is similar
to those of T. cruzi (PDB ID 1ML3; Castilho et al., 2003), T. brucei
(PDB ID 2X0N; Vellieux et al., 1993), and L. mexicana (PDB
ID 1GYP; Kim et al., 1995), with r.m.s.d. values of 1.35, 1.30,
and 1.30 Å over 320 aligned Cα atoms, respectively. Similarly,
superposition of AvGAPDH with the human and rabbit GAPDH
enzymes can be achieved with r.m.s.d. values of 1.26 Å (fully
occupied by NAD+) and 1.30 Å (devoid of NAD+). While most
structural differences are located in flexible surface loops, several
unique features stand out when the NAD+-binding site and,
especially, the adenosyl-binding pocket, are compared across
GAPDH enzymes from different species (Bressi et al., 2001;
Kennedy et al., 2001; Figure 8).
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FIGURE 7 | Evolutionary conservation. Unrooted phylogenetic tree of selected GAPDH sequences calculated with the maximum-likelihood software PhyML with
branch supports shown at every node. Sequences are colored according to taxonomic grouping, with bacteria in yellow, plants and algae in green, yeasts in orange,
arthropods in purple, mammals in blue, and protozoa in red. The multiple sequence alignment is provided in the SI. This figure was produced with FigTree
(http://tree.bio.ed.ac.uk/software/figtree/).
The most notable difference between AvGAPDH and the
human enzyme concerns the anchoring of the adenine ring
into the hydrophobic pocket (Figure 4C). It is precisely the
less conserved regions between the GAPDH from pathogens
and human GAPDH that are appealing for the design of
selective inhibitors, which can impair pathogen viability without
compromising the host GAPDH function. Thus, for years,
changes in the hydrophobicity of the areas adjacent to the
N6 position of the adenine ring and the O2′of the ribose of
NAD+ molecule have been successfully used as anchor points
for selective inhibitors of GAPDH from pathogens such as
TmGAPDH, TvGAPDH, and TcGAPDH (Figure 8C). In the
crystal structure of AvGAPDH, the side chains of Leu50 and
Thr114-Gly115-Phe116-Tyr117 surround the NAD+ binding
pocket around the adenine ring (Figure 8). Indeed, the electron
density map contoured at 1 σ level confirms the unusual presence
of Tyr117 instead of the highly conserved Phe (Figures 3A,
4C, 8) observed in nearly all sequences, with the exception
of rat, human sperm and SaGAPDH (Figure 8A). In all cases,
a conserved water mediates the interaction between the OH
group of Tyr117 side chain with the N5′ atom in the adenine
ring (Figures 8A–C). Furthermore, another feature unique to
AvGAPDH is the presence of the minimalist loop Ala95-
Ala97-Asp96 nearby the position occupied by the adenine ring
of NAD+ (Figures 3A, 4C, 8A). The intrusion of this loop
facilitates the interaction of Ala95 main-chain with the adenine
ring. The tandem Phe116-Tyr117 is also missing along several
pathogenic bacteria, both Gram-positive (e.g., Staphylococcus and
Streptococcus spp. and Bacillus anthracis) and Gram-negative
(e.g., Bartonella, Brucella, Borrelia, and Synechococcus spp.).
Also, GAPDH from some thermophilic bacteria (e.g., Thermus,
Aquifex, and Thermosynechococcus spp.) lack an equivalent
residue to Tyr117. These differences can be exploited for the
design of drugs targeting the N6 position of the adenine
ring (Figure 7). On the other hand, the ribose ring of the
NAD+ cofactor interacts with Pro207, which is conserved in
HsGAPDH (Figure 3A). The narrow groove between the Pro207
and Pro36-Phe37 is a distinguishing feature used to search for
selective drugs (Figure 3A). A relevant example is 2′-deoxy-2′-
(m-methoxybenzamido)adenosine (MBDA), a curved molecule
that binds selectively to TcGAPDH while it does not bind to
HsGAPDH due to steric hindrance (MBDA; 50). For AvGAPDH,
the equivalent residue is Phe30 and Leu50-Thr51, whose Cα’s
are 0.5 Å are displaced between them. This will probably make
NAD+ inhibitors derived with substitutions in O2′ position less
effective.
The functional cavities and interfaces of AvGAPDH that are
most divergent with respect to the human GAPDHs suggest
themselves as potential targets for drug discovery. In AvGAPDH
the hydrophobic residues that surround the adenine ring have a
distribution resembling more closely the configuration observed
in the glycosomal GAPDHs than the human liver enzyme.
Specifically, Leu50 occupies in AvGAPDH the position of Pro36-
Phe37 in the human liver GAPDH and Thr114, Phe116, and
Tyr117 shield the opposite side of the adenine pocket (Figure 4C
and Supplementary Figure 5). Based on this observation, other
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FIGURE 8 | Comparison of the NAD+ adenine ring-binding subsite. Ribbon representation of the NAD+ binding pocket in AvGAPDH with the cofactor and the
residues that lock the adenine ring of the cofactor (in gray) shown in sticks (in gold). Residues from the neighboring chain are labeled with an asterisk and their carbon
atoms are shown in violet. (A) Comparison with S. aureus SaGAPDH adenosyl-binding pocket (PDB 3K73; pink). (B) L. mexicana LmGAPDH (PDB 1GYP; gray). (C)
Trypanosoma cruzi TcGAPDH (PDB 1ML3; blue). The figure was produced with PyMOL (Schrodinger LLC). (D) Multiple sequence alignment of GAPDH from
A. vaginae, S. aureus, L. Mexicana, and T. cruzi. Adenosyl-binding residues are boxed.
strategies than those used for TvGAPDH, LmGAPDH, and
TcGAPDH have to be adopted to inhibit AvGAPDH, and we
propose that nucleoside analogs such as the adenosine derivatives
like MBDA (MBDA; 50) represent an interesting starting point
for future developments.
DISCUSSION
Crystal Structure of AvGAPDH
The crystal structure of AvGAPDH reported herein at 2.19 Å
has been refined to convergence with Rwork/Rfree = 0.177/0.226
and the final model exhibits excellent stereochemistry (Table 1).
Although the overall fold of AvGAPDH is highly conserved
when compared with reported GAPDH structures (Figure 1),
there are distinctive structural features in AvGAPDH with
important consequences for potential protein binding partners
as well as for the discovery of selective inhibitors (Figures 4,
8). The availability of the first high-quality, high-resolution
crystal structure of a complement immunoevasive GAPDH can
generate insights into the mechanistic basis for complement
interference as well as provide a template for inhibitor
search.
As previously reported, streptococcal GAPDH can function
as an immunoevasion factor by sequestering in-situ produced
C5a on the pathogen’s surface during the lytic or terminal
phase of complement activation (Terao et al., 2006). Terao et al.
concluded that the N-terminal region of SpGAPDH (residues
1−165) was the likely C5a-recognition motif (Terao et al.,
2006). The homologous region in AvGAPDH spans residues
1−185 and is reasonably well conserved, with 56.4% identity
and 66.4% similarity (compare with the full-length sequence
alignment, with 64.9% identity and 70.7% similarity). Since the
structure of the N-terminal region of GAPDH enzymes is partly
defined by the NAD+-binding pocket, these loops share an
overall structural organization and they differ mostly by the
array of residues that become solvent exposed. In particular, the
structure of residues 1−185 in AvGAPDH and the equivalent
segment of the closely related SaGAPDH (Mukherjee et al., 2010)
trace roughly equivalent spatial trajectories over and above the
cofactor-binding site. This is the proposed C5a-docking surface,
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which provides a relatively flat and flexible platform that could
accommodate the binding of the small C5a molecule.
This structure and sequence-backed findings suggest that
GAPDH enzymes from pathogenic bacteria located over widely
diverse evolutionary distances could however be equipped with
conserved C5a-binding surfaces. Since S. pyogenes, A. vaginae,
and S. typhimurium are all important human pathogens, the
immunoevasive capacity detected for bacterial GAPDH might
conceivably have been selected for in the context of infection.
If this hypothesis holds true, it would imply that the pattern of
C5a sequestration by bacterial GAPDH should be extended to
a large diversity of Gram-positive and Gram-negative bacterial
pathogens. A second implication would consist in the opening of
a window of opportunity for the treatment of antibiotic-resistant
bacterial infections with complement stimulatory therapies, e.g.,
by releasing C5a blockade.
AvGAPDH as a Complement
Immunoevasive Factor through C5a
The relatively high sequence identity and similarity shared
between SpGAPDH and AvGAPDH suggested that the latter
could also elicit C5a sequestration. The experimental evidence
presented hereby corroborates a likely role for AvGAPDH
as an immunoevasive factor. Of the experiments performed,
ligand blotting using biotinylated-C5a (Figure 5A) had been
previously used with SpGAPDH to establish its interaction
with C5a (Terao et al., 2006). In addition, we have carried
out highly specific cross-linking experiments with BMOE to
prove a physical interaction between AvGAPDH and C5a
(Figure 5B). BMOE crosslinks protein thiol groups <8-Å
apart, thereby completely avoiding spurious covalent complexes.
Additional ELISA experiments corroborated the significance of
the AvGAPDH-C5a interaction originally identified by the ligand
blotting and cross-linking experiments. The previous three in
vitro approaches converged on a model whereby AvGAPDH and
C5a can form a complex. Unfortunately, we could not isolate
a stable complex by chromatography to subject it to structural
analysis. Given the evidence at hand and that from previous
studies (Terao et al., 2006), we attribute this behavior to the
complex environment wherein this interaction will occur in vivo,
which might potentiate the physical association and/or provide a
more favorable context for the interaction (e.g., on the cell-wall
surface). Future research should tackle the issue of context and
presentation for the host-pathogen interaction described in this
work.
To seek independent verification for the AvGAPDH-C5a
interaction, we tested the ability of soluble and surface-
immobilized AvGAPDH, CpGAPDH, and SpGAPDH to inhibit
neutrophil chemoattraction, which was triggered with native
C5a generated in situ by incubating C5-containing serum
with zymosan (Figure 6B). Since at least AvGAPDH and
SpGAPDH are C5a interactors, the most likely mechanism for
neutrophil migration blockade is physical sequestration of C5a
by its binding partners. The results convincingly show that
AvGAPDH and, to a similar extent, SpGAPDH, are capable
of reversing the C5a-induced chemoattraction of neutrophils
in a cell migration assay. CpGAPDH, in contrast, was less
effective than either AvGAPDH or SpGAPDH in sequestering
C5a. The observed inhibition was markedly stronger when
surface-immobilized AvGAPDH was used as compared with the
effect of soluble proteins, thereby indicating that the precise
structural-chemical context where the GAPDH-C5a interaction
can occur is bound to play a significant biological role. The
fact that undecorated agarose beads were incapable of blocking
neutrophil migration rules out an inhibitory role for the carrier
material.
When combined, the ligand blotting, cross-linking, ELISA
interaction assays, and cell migration inhibition assays together
offer a coherent view of AvGAPDH (and SpGAPDH) as a
virulence factor. In one of its manifold moonlighting functions,
secreted and/or surface-immobilized AvGAPDH bears the
potential to titrate out serum C5a from the infected areas
where the anaphylatoxin is generated. As such, this complement
down-regulatory mechanism could be at play in those cases
where BV has been associated with a strong pro-inflammatory
response as a result of the secretion of IL-6 and IL-8 (Fichorova
et al., 2011; Doerflinger et al., 2014).
GAPDH as a Chemotherapeutic Target for
A. vaginae
The two most salient differences between GAPDH from
A. vaginae and the human liver enzyme are localized in the
adenosine binding subpocket of NAD+ and around the S loop
that faces it (Figure 4). These and other differences have been
exploited for the successful design of anti-GAPDH compounds
against trypanosomatids that escape trapping in the liver. In
a similar manner, we reason that the observed differences
could be exploited to discover compounds (or reuse anti-
trypanosomatid GAPDH drugs) against AvGAPDH. This is a
pressing matter owing to the inefficiency of current therapeutic
options for the treatment of BV caused by the swift appearance
of antibiotic resistant bacterial strains. When the AvGAPDH
structure is compared with those of trypanosomatids, the
pattern of conserved and diverging structural elements presents
differences with those described for the comparison with the
human liver enzyme (Figure 8). Interestingly, naïve chemical
modeling of known anti-trypanosomatid GAPDH inhibitors into
theAvGAPDH active site suggests that these well-studied families
of compounds could be effective as inhibitors and, therefore,
represent new therapeutic opportunities for BV.
The significance of the high-resolution AvGAPDH structure
for drug discovery initiatives targeting human BV might be large
if A. vaginae infections rely greatly on a functional glycolytic
pathway. In principle, an effective anti-GAPDH agent that binds
into the active site could as well disrupt the long loop that covers
the NAD+ cofactor and is involved in C5a binding, therefore
suggesting the interesting possibility that such an inhibitor could
both down-regulate the glycolytic flux and also perturb C5a
recognition by AvGAPDH.
Future investigations will address whether compounds related
to the available anti-trypanosomatid GAPDH drugs can indeed
effectively inhibit AvGAPDH.
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FIGURE 9 | Model for the immunoevasive function of A. vaginae GAPDH through C5a sequestration. (A) A C5a gradient generated by the activation of the
lytic phase of complement’s alternative pathway leads to the recruitment of neutrophils to the site of infection through the activation of pro-inflammatory signaling
cascades via C5a receptor (C5aR1) stimulation. (B) Cell-wall associated AvGAPDH traps in-situ generated C5a, thereby disrupting the chemotactic gradient and
effectively “blinding” neutrophils about the presence of the bacterial pathogen. Macromolecular structures are shown to scale and represented as sphere models. C5
(PDB ID 3CU7) (Fredslund et al., 2008) is colored according to its domain structure; C345c is shown in pale green, the C5a anaphylatoxin in red, the β-chain in light
pink, and the α-chain in gray. In C5b-C6 (PDB ID 4A5W) (Hadders et al., 2012), C5b is colored as C5 (except for the anaphylatoxin domain, which is missing in C5b)
and C6 is colored in cyan. C5a (PDB ID 3HQA) (Cook et al., 2010) is shown in the same color as the anaphylatoxin domain of C5. The transmembrane region of
C5aR1 was modeled the crystal structure of ligand-free rhodopsin (PDB ID 3CAP) (Park et al., 2008) without loops and colored in violet.
Is Complement Immunoevasion a Widely
Shared Moonlighting Property of GAPDH?
There is accumulating persuasive evidence that metabolic
enzymes, especially abundant enzymes such as the glycolytic
enzymes GAPDH and enolase, are able to perform important
functions unrelated to their cognate catalytic activity (Terao et al.,
2006; Agarwal et al., 2012; Terrasse et al., 2012; Wang and Jeffery,
2016). These so-called moonlighting functions of predominantly
cytosolic enzymes are typically deployed at specific subcellular
compartments or locations (e.g., cell nucleus, mitochondria,
plasma membrane) or in extracellular contexts. The underlying
causes that would explain how glycolytic enzymes came to
develop these functions are not yet fully appreciated, although it
is now clear that these additional functions have been selected
for during evolution and are not merely a side effect of
mislocalization or chance occurrence. Most of the hypotheses
that have been advanced include the high concentration of
these enzymes as a driver factor for their selection to fulfill
accessory functions in particular contexts, under the rationale
that reassigning existing genes and proteins for new functions
is economical and efficient. This strategy appears particularly
compelling for genome-encoded virulence factors, where two
selective pressures (growth inside the host and immunoevasion)
become coupled through a very abundant, multifunctional
enzyme like GAPDH.
The involvement of the extracellular GAPDH of S. pyogenes in
C5a sequestration (Terao et al., 2006) and of the S. pneumoniae
enzyme in C1q binding (Terrasse et al., 2012) provide
reference cases for the existence of complement immunoevasion
mechanisms in streptococcal infections that depend on the
moonlighting action of GAPDH. The extension of these
mechanisms to GAPDH from other Gram-positive pathogenic
bacteria that share significant sequence similarity with S. pyogenes
GAPDH is relevant and intriguing. Firstly, because GAPDH is
an essential gene present in all bacteria and could therefore be
seen as a universal virulence factor tasked with down-regulating
complement-mediated recruitment of neutrophils to sites of
infection. Secondly, because sequence similarity across bacterial
GAPDH genes cuts across phylogenetic groups and reveals
broad patterns of horizontal transfer events, thereby indicating
the potential for widespread dispersion of immunoevasive
GAPDH sequences. One such example is the high sequence
similarity between A. vaginae (a Gram-positive bacterium) and
S. aureus (a Gram-negative proteobacterium), which would
suggest a potential for C5a sequestration for S. aureus GAPDH.
If this were the case, interference with the normal function
of the complement anaphylatoxin-mediated signaling could
provide a general mechanism for down-modulating the innate
immune response. In the context of the infection biology
of A. vaginae, deploying molecules capable of depressing the
spread of anaphylatoxins away from the site of infection would
be advantageous for the bacterium to proliferate (Figure 9).
In addition, the depletion of C5a would obviously help the
proliferation of the complex community of bacteria that
cooperate with A. vaginae in establishing BV, including G.
vaginalis and other associated bacteria.
Might then reverting this C5a sequestration mechanism
offer therapeutic opportunities against bacterial infections?
Bacterial pathogens wreak havoc by the action of specialized
virulence factors and by aggressive proliferative behaviors,
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none of which relies solely on immunoevasive mechanisms.
Down-regulating pro-inflammatory responses mediated by C5a
can help the pathogen expand at the onset of an infection,
whereby escaping the watch of innate immunity may be crucial
for its initial survival. Combination therapies attacking other
aspects of bacterial pathogenesis while simultaneously freeing
the complement system (e.g., C5a and C1q) from interfering
influences from bacterial molecules such as GAPDH could result
in a more effective strategy, whereby the chance for decimated
bacterial populations to endure through the antibiotic treatment
and thrive back again as soon as antibiotic treatment stops
would be minimized. As further knowledge accumulates as to the
potentially beneficial effects of modulating complement protein
factors during infections, these strategies should be seriously
considered, as their applicability would span a very wide range
of bacterial pathogens.
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